G1 Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2016 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: G1 Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2016 to Q2 2024.
G1 Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$3.54M, a 131% decline year-over-year.
G1 Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$37.9M, a 43.2% increase year-over-year.
G1 Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$39.5M, a 71% increase from 2022.
G1 Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$136M, a 4.41% increase from 2021.
G1 Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$142M, a 47.7% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2024	-$37.9M	-$3.54M	-$15.1M	-131%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-08
Q1 2024	-$22.8M	-$9.05M	+$16.7M	+64.9%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-01
Q4 2023	-$39.5M	-$8.93M	+$22M	+71.1%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-28
Q3 2023	-$61.5M	-$16.4M	+$5.18M	+24%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-01
Q2 2023	-$66.7M	$11.5M	+$48.5M		Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-08
Q1 2023	-$115M	-$25.7M	+$21M	+45%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-01
Q4 2022	-$136M	-$30.9M	+$6.7M	+17.8%	Oct 1, 2022	Dec 31, 2022	10-K	2023-03-01
Q3 2022	-$143M	-$21.5M	+$19.6M	+47.6%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-01
Q2 2022	-$162M	-$37M	+$1.23M	+3.22%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-02
Q1 2022	-$164M	-$46.8M	-$21.2M	-83.2%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-03
Q4 2021	-$142M	-$37.6M	-$13.5M	-56%	Oct 1, 2021	Dec 31, 2021	10-K	2023-03-01
Q3 2021	-$129M	-$41.1M	-$31.4M	-322%	Jul 1, 2021	Sep 30, 2021	10-K	2023-03-01
Q2 2021	-$97.6M	-$38.2M	-$7.37M	-23.9%	Apr 1, 2021	Jun 30, 2021	10-K	2023-03-01
Q1 2021	-$90.2M	-$25.5M	+$6.29M	+19.8%	Jan 1, 2021	Mar 31, 2021	10-K	2023-03-01
Q4 2020	-$96.5M	-$24.1M	+$12.5M	+34.1%	Oct 1, 2020	Dec 31, 2020	10-K	2022-02-23
Q3 2020	-$109M	-$9.75M	+$24.3M	+71.4%	Jul 1, 2020	Sep 30, 2020	10-K	2022-02-23
Q2 2020	-$133M	-$30.8M	+$1.76M	+5.41%	Apr 1, 2020	Jun 30, 2020	10-K	2022-02-23
Q1 2020	-$135M	-$31.8M	-$5.94M	-23%	Jan 1, 2020	Mar 31, 2020	10-K	2022-02-23
Q4 2019	-$129M	-$36.6M	-$10.5M	-40.1%	Oct 1, 2019	Dec 31, 2019	10-K	2021-02-24
Q3 2019	-$119M	-$34M	-$13.2M	-63.4%	Jul 1, 2019	Sep 30, 2019	10-K	2021-02-24
Q2 2019	-$105M	-$32.6M	-$10.9M	-50.5%	Apr 1, 2019	Jun 30, 2019	10-K	2021-02-24
Q1 2019	-$94.4M	-$25.9M	-$5.16M	-24.9%	Jan 1, 2019	Mar 31, 2019	10-K	2021-02-24
Q4 2018	-$89.3M	-$26.1M	-$8.8M	-50.9%	Oct 1, 2018	Dec 31, 2018	10-K	2020-02-26
Q3 2018	-$80.5M	-$20.8M	-$4.89M	-30.7%	Jul 1, 2018	Sep 30, 2018	10-K	2020-02-26
Q2 2018	-$75.6M	-$21.7M	-$6.27M	-40.8%	Apr 1, 2018	Jun 30, 2018	10-K	2020-02-26
Q1 2018	-$69.3M	-$20.7M	-$8.35M	-67.4%	Jan 1, 2018	Mar 31, 2018	10-K	2020-02-26
Q4 2017	-$61M	-$17.3M	-$6.88M	-66.1%	Oct 1, 2017	Dec 31, 2017	10-K	2019-02-28
Q3 2017	-$54.1M	-$15.9M	-$9.32M	-141%	Jul 1, 2017	Sep 30, 2017	10-K	2019-02-28
Q2 2017	-$44.8M	-$15.4M	-$7.95M	-107%	Apr 1, 2017	Jun 30, 2017	10-K	2019-02-28
Q1 2017	-$36.8M	-$12.4M	-$6.43M	-108%	Jan 1, 2017	Mar 31, 2017	10-K	2019-02-28
Q4 2016	-$30.4M	-$10.4M			Oct 1, 2016	Dec 31, 2016	10-K	2018-02-21
Q3 2016		-$6.61M			Jul 1, 2016	Sep 30, 2016	10-K	2018-02-21
Q2 2016		-$7.43M			Apr 1, 2016	Jun 30, 2016	10-K	2018-02-21
Q1 2016		-$5.95M			Jan 1, 2016	Mar 31, 2016	10-K	2018-02-21

* An asterisk sign (*) next to the value indicates that the value is likely invalid.